Roberto Bolli, M.D., D.Sc. (Hon) FAHA, FACC

• Professor of Medicine, Physiology and Biophysics
• Jewish Hospital Heart and Lung Institute Distinguished Chair in Cardiology
• Director, Institute of Molecular Cardiology
• Distinguished University Scholar

UofL Physicians Outpatient Center
401 East Chestnut Street, Ste. 310
Louisville, KY 40202

502-852-1837- Academic Office
502-588-7010 - Patient Appointments

Get To Know Dr. Bolli

Featured Publications

• Abouleisa RRE, Tang XL, Ou Q, Salama AM, Woolard A, Hammouri D, Abdelhafez H, Cayton S, Abdulwali SK, Arai M, Sithu ID, Conklin DJ, Bolli R, Mohamed TMA. Gene therapy encoding cell cycle factors to treat chronic ischemic heart failure in rats. Cardiovasc Res. 2024 Mar 13;120(2):152-163. doi: 10.1093/cvr/cvae002. PMID: 38175760; PMCID: PMC10936750.
• Bolli R, Ippolito L, Volarevic V. A new era for Molecular and Cellular Biochemistry. Mol Cell Biochem. 2023 Nov;478(11):2405-2407. doi: 10.1007/s11010-023-04864-3. PMID: 37776408.
• Tang XL, Bolli R. Repeated Intravenous Administration of Mesenchymal Stromal Cells Produces Cumulative Beneficial Effects in Chronic Ischemic Cardiomyopathy. Tex Heart Inst J. 2023 Oct 12;50(5):e238244. doi: 10.14503/THIJ-23-8244. PMID: 37840224; PMCID: PMC10658144.
• Tang XL, Nasr M, Zheng S, Zoubul T, Stephan JK, Uchida S, Singhal R, Khan A, Gumpert A, Bolli R, Wysoczynski M. Bone Marrow and Wharton's Jelly Mesenchymal Stromal Cells are Ineffective for Myocardial Repair in an Immunodeficient Rat Model of Chronic Ischemic Cardiomyopathy. Stem Cell Rev Rep. 2023 Oct;19(7):2429-2446. doi: 10.1007/s12015-023-10590-6. Epub 2023 Jul 28. PMID: 37500831; PMCID: PMC10579184.
• Salama ABM, Abouleisa RRE, Ou Q, Tang XL, Alhariry N, Hassan S, Gebreil A, Dastagir M, Abdulwali F, Bolli R, Mohamed TMA. Transient gene therapy using cell cycle factors reverses renin-angiotensin-aldosterone system activation in heart failure rat model. Mol Cell Biochem. 2023 Jun;478(6):1245-1250. doi: 10.1007/s11010-022-04590-2. Epub 2022 Oct 25. PMID: 36282351; PMCID: PMC10126184.
• Nong Y, Guo Y, Ou Q, Gumpert A, Tomlin A, Zhu X, Bolli R. PU.1 inhibition does not attenuate cardiac function deterioration or fibrosis in a murine model of myocardial infarction. Mol Cell Biochem. 2023 Apr;478(4):927-937. doi: 10.1007/s11010-022-04561-7. Epub 2022 Sep 17. PMID: 36114991; PMCID: PMC10091869.
• Bolli R, Solankhi M, Tang XL, Kahlon A. Cell therapy in patients with heart failure: a comprehensive review and emerging concepts. Cardiovasc Res. 2022 Mar 16;118(4):951-976. doi: 10.1093/cvr/cvab135. PMID: 33871588; PMCID: PMC8930075..
• Bolli R, Tang XL. New insights into cardioprotection, gained by adopting the CAESAR standards of rigor. Basic Res Cardiol. 2022 Nov 11;117(1):57. doi: 10.1007/s00395-022-00964-1. PMID: 36367590.
• Bolli R, Tang XL. Clinical trials of cell therapy for heart failure: recent results warrant continued research. Curr Opin Cardiol. 2022 May 1;37(3):193-200. doi: 10.1097/HCO.0000000000000956. PMID: 35612934; PMCID: PMC9178910.
• Taylor DA, Chacon-Alberty L, Sampaio LC, Hierro MGD, Perin EC, Mesquita FCP, Henry TD, Traverse JH, Pepine CJ, Hare JM, Murphy MP, Yang PC, March KL, Vojvodic RW, Ebert RF, Bolli R; Cardiovascular Cell Therapy Research Network (CCTRN). Recommendations for nomenclature and definition of cell products intended for human cardiovascular use. Cardiovasc Res. 2022 Aug 24;118(11):2428-2436. doi: 10.1093/cvr/cvab270. PMID: 34387303; PMCID: PMC9400434.
• Bolli R, Tang XL, Guo Y, Li Q. After the storm: an objective appraisal of the efficacy of c-kit+ cardiac progenitor cells in preclinical models of heart disease. Can J Physiol Pharmacol. 2021 Feb;99(2):129-139. doi: 10.1139/cjpp-2020-0406. Epub 2020 Sep 16. PMID: 32937086; PMCID: PMC8299902.